March 8, 2001 |
Affymetrix Inc., the largest maker of gene chips used in drug research, said it found flaws in one line of products and offered replacements. The Santa Clara, Calif.-based company found errors in data taken from mouse genes used to design one type of the company's gene chips, glass wafers with DNA fragments affixed to their surfaces. Replacing the defective chips may cost up to $4 million, the company said in a filing with the Securities and Exchange Commission.
June 5, 1989
Barry D. Gingell, 34, a doctor who campaigned to speed up the testing of experimental drugs for AIDS and to increase access to them. For nearly two years, Gingell was the top medical expert for the Gay Men's Health Crisis, a New York City service and education organization seeking to combat the disease. Gingell served on the National Academy of Sciences, the Society of Infectious Diseases, the Community Research Initiative and the AIDS Resource Center. "Drug research is going at a maddeningly slow pace," he told the New York Times 15 months ago. "Right now at least 10 to 20 drugs show promising results elsewhere in the world or in the laboratory but many potential therapies aren't being tested."
February 9, 2012 |
A drug that has been approved for the treatment of a type of skin cancer since 1999 appears to reverse Alzheimer's symptoms -- in mice. Case Western Reserve University School of Medicine neuroscientist Gary Landreth and colleagues reported Thursday that bexarotene quickly cleared away beta-amyloid plaque, believed to cause the cognitive deficits of Alzheimer's disease, from the brains of genetically engineered mice. Mice who received bexarotene...
March 17, 1995 |
The deaths of five of 15 participants in a catastrophic 1993 hepatitis B drug study on the experimental drug FIAU were unavoidable, the Institute of Medicine said in a report released Thursday. "An elaborate system is in place to protect patients during clinical trials and serious harm is rare," said Dr. Morton Swartz, chairman of the institute panel that conducted the review. "Findings from previous animal and human tests . . . didn't expose this drug's life-threatening side effects.
June 21, 2004
It's human nature to talk about our good deeds while keeping mum about the bad ones. This applies not only to schoolkids and presidents but to medical researchers. According to several recent investigations, scientists are far more likely to publish the results of a drug study when it concludes that the drug works than when it indicates that the drug is ineffective or harmful. For years, drug industry lobbyists have thwarted most efforts to require disclosure of drug research.
July 29, 1989
Red Patterson's picks (July 18) of the all-time greatest teams were far off base. What about the Yankees from 1960 through '64, especially the '61 team with Mickey Mantle and Roger Maris, who combined for 115 home runs? Whitey Ford led a solid group of starters with a 25-4 record, and they had a tremendous bullpen, led by Luis Arroyo. They walked all over Cincinnati in five games in the World Series. And this team is not even mentioned. And how about the Cincinnati team of the mid-'70s?
March 10, 1990 |
A government test has determined that a red dye used in many lipsticks is a powerful herbicide capable of killing marijuana plants, prompting some Bush Administration officials to propose using the dye in an airborne offensive against domestic marijuana cultivation.
September 3, 1989
Harry Bernstein's otherwise comprehensive July 18 column on drug prices ("Soaring Prices of Drugs Squeeze Workers, Pharmacists") suffered from one error in understanding the drug manufacturing industry. The column mentioned "the huge amounts of money they spend on research and development." But many studies have shown that the industry as a whole--one of the most profitable industries in the United States--spends less than 10% of its revenue on research and development. And then the drug companies spend 80% of their income on marketing.
June 5, 2004
Re "Activists Put Drug Research on Chopping Block," Commentary, June 1: I was described by James Glassman and Nick Schulz as a "left-wing activist" who is engaged in a "relentless campaign against technological innovation" spreading "Luddite nonsense that kills people." Allow me to respond. What has them riled up is Essential Inventions' petition asking the Bush administration to allow generic drug companies to use six government-funded patents relating to the AIDS drug ritonavir, sold now under the trade name Norvir.
July 3, 1992 |
Astronauts on the space shuttle Columbia conducted research Thursday for the battle against AIDS. Payload specialist Lawrence DeLucas--his hands gloved and placed inside a transparent, sealed container--worked with an enzyme known as HIV reverse transcriptase, a protein compound targeted by current AIDS drugs. The crew has at least five compounds on board related to the virus that causes AIDS and are working with more than 20 other compounds as well.